Aerosol characterization specialist Proveris Scientific has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member, the company announced. IPAC-RS now has a total of 16 member pharmaceutical companies and 5 associate members. Proveris Scientific CEO Dino Farina commented, “We are excited to join … [Read more...] about Proveris Scientific joins IPAC-RS as an associate member
News
RDD Europe 2017 focused on new technology
RDD Europe 2017 which took place April 25-28, 2017 at the Palais des Congrès in Antibes, France, drew almost 500 attendees from 32 countries, the largest RDD Europe meeting to date, organizers said. Throughout the course of the program and exhibition, the focus was on new technology, especially in the form of connected devices, with a number of presenters also … [Read more...] about RDD Europe 2017 focused on new technology
Positive Phase 1 results for Dauntless’s intranasal octreotide
Dauntless Pharmaceutical has announced positive results from a Phase 1 trial of its DP1038 intranasal octreotide acetate, which it is developing for the treatment of acromegaly and neuroendocrine tumors. The company had announced initiation of the trial in February 2017. The PK/PD trial first compared 3 doses of intranasal octreotide acetate to 100 μg of … [Read more...] about Positive Phase 1 results for Dauntless’s intranasal octreotide
Pulmatrix appoints Ted Raad as Chief Business Officer
Inhaled drug developer Pulmatrix has announced the appointment of former Sunovion Respiratory and CNS Business Unit Head Ted Raad as Chief Business Officer. Raad was most recently Chief Commercial Officer at Option Care, the home infusion services subsidiary of Walgreens. Pulmatrix CEO Robert Clarke said, "Ted is a proven leader in the commercial development of … [Read more...] about Pulmatrix appoints Ted Raad as Chief Business Officer
AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease
AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris's inhaled anticalin therapies, Pieris said. In the near term, AstraZeneca will also provide $12.5 million for a Phase 1 trial of Pieris's lead candidate PRS-060, which is expected to … [Read more...] about AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease
Phase 3 trial of intranasal midazolam meets primary endpoint
Upsher Smith subsidiary Proximagen has announced that the Phase 3 ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray) study of its USL261 intranasal midazolam for the treatment of seizure clusters, met its primary efficacy endpoint. Proximagen says that it plans to submit a 505(b)(2) NDA for the product by the end of the year. The primary … [Read more...] about Phase 3 trial of intranasal midazolam meets primary endpoint
H&T Presspart announces partnership with Hovione and launches the PowdAir Plus DPI
H&T Presspart has announced its acquisition of global rights to a capsule-based dry powder inhaler developed by Hovione. H&T Presspart will manufacture and commercialize the DPI, which will be marketed as PowdAir Plus. According to the announcement, the two companies will continue to collaborate. The PowdAir Plus DPI, which was designed with the needs of developing … [Read more...] about H&T Presspart announces partnership with Hovione and launches the PowdAir Plus DPI
NIH announces funding opportunity for nasal delivery of CNS therapeutics
The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business Technology Transfer (STTR) program Both FOAs say that their purpose is to "is to develop a nasal delivery formulation … [Read more...] about NIH announces funding opportunity for nasal delivery of CNS therapeutics
Cohero announces the appointment of Joe Condurso as CEO
Digital health company Cohero Health has announced the appointment of Joe Condurso as CEO. Cohero and its partner Presspart introduced their eMDI smart inhaler system at DDL in 2016. Condurso was most recently CEO of PatientSafe Solutions and previously worked at CareFusion (now Becton Dickinson) and a number of other medical companies over a 30-year … [Read more...] about Cohero announces the appointment of Joe Condurso as CEO
Teva launches AirDuo RespiClick and authorized generic simultaneously in US
Teva has launched both the AirDuo RespiClick fluticasone propionate/salmeterol DPI and an authorized generic version of the product in the US, the company said. The FDA approved 3 doses of AirDuo RespiClick for the treatment of asthma in patients aged 12 years and over earlier this year. The company said that it expects the majority of sales to come from the … [Read more...] about Teva launches AirDuo RespiClick and authorized generic simultaneously in US